BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.

By F. Hilberg, G. Roth, Martin Krssák, Susanna Kautschitsch, W. Sommergruber, U. Tontsch-Grunt, P. Garin‐Chesa, G. Bader, A. Zoephel, Jens Quant and 2 more. Cancer Research, 2008

994 citations recorded by the source corpus.

Subfields: Cancer Research, Hepatology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/7d5aa55a5660996a72bbc069805e0a182cbea133

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. A. Adamis
2. N. Ferrara
3. Rakesh K. Jain
4. H. Gerber

In Molecular Biology

1. A. Adamis
2. N. Ferrara
3. Rakesh K. Jain
4. Peter Carmeliet
5. R. Apte
6. Daniel Chen
7. H. Gerber

Citations in the corpus

• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Also, preclinical studies testing high doses of VEGFR RTKIs have reported increased tumour aggressiveness and metastasis 130 .”